A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by Lawson Health Research Institute.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT00788463
First received: November 7, 2008
Last updated: NA
Last verified: November 2008
History: No changes posted

November 7, 2008
November 7, 2008
March 2008
March 2009   (final data collection date for primary outcome measure)
Difference in overall quality of life as measured by the Rhinitis Quality of Life Questionnaire [ Time Frame: 0, 1, 3, 6 months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Difference in Nasal Airflow Resistance as measured an anterior rhinomanometry [ Time Frame: 0, 1, 3, 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps
A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps

The purpose of this study is to determine if intranasal Beclomethasone delivered by aerosol or spray is more effective in treatment of nasal polyps.

Aqueous and aerosol delivery of intranasal corticosteroids has never been directly compared previously in patients with nasal polyps and it is unknown whether one is superior.

This objective of this study is to compare the efficacy of intranasal beclomethasone by two different delivery systems, aerosol and aqueous spray in patients with nasal polyps. Primary endpoint is the difference in the overall quality of life as measured by the Rhinitis Quality of Life Questionnaire. The secondary endpoint is the change in Nasal Airflow Resistance as measured by rhinomanometry.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Nasal Polyps
  • Drug: Intranasal Beclomethasone aerosol
    Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
    Other Name: QVAR
  • Drug: Intranasal Beclomethasone spray
    Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
  • Experimental: Aerosol
    Intervention: Drug: Intranasal Beclomethasone aerosol
  • Active Comparator: Spray
    Intervention: Drug: Intranasal Beclomethasone spray

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
December 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years old
  • New diagnosis of nasal polyps confirmed by two physicians

Exclusion Criteria:

  • Intranasal corticosteroid use within 4 weeks
  • Oral corticosteroids use within 4 weeks
  • Oral corticosteroid inhalation (ie for treatment of asthma or COPD) of Budesonide >400ug daily, Fluticasone >250ug daily, Beclomethasone >400ug daily
  • Contraindication to intranasal corticosteroid
  • Inability to give informed consent
  • Participation in another clinical trial
  • Pregnancy (or not using effective method of contraception) or lactation
  • Cystic fibrosis
Both
18 Years and older
No
Contact: Jorge A Mazza, MD 519-685-8500 ext 58277 jmazza@uwo.ca
Canada
 
NCT00788463
R-06-542, 12801
No
Jorge Mazza, London Health Sciences Centre
Lawson Health Research Institute
Not Provided
Principal Investigator: Jorge A Mazza, MD University of Western Ontario, Canada
Lawson Health Research Institute
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP